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Abstract This paper presents the first systematic review
and meta-analysis of neuropsychological and brain mor-
phometry studies comparing posterior cortical atrophy
(PCA) to typical Alzheimer’s disease (tAD). Literature
searches were conducted for brain morphometry and neuro-
psychological studies including a PCA and a tAD group.
Compared to healthy controls (HC), PCA patients exhibited
significant decreases in temporal, occipital and parietal gray
matter (GM) volumes, whereas tAD patients showed exten-
sive left temporal atrophy. Compared to tAD patients, par-
ticipants with PCA showed greater GM volume reduction in
the right occipital gyrus extending to the posterior lobule. In
addition, PCA patients showed less GM volume loss in the
left parahippocampal gyrus and left hippocampus than tAD
patients. PCA patients exhibit significantly greater impair-
ment in Immediate Visuospatial Memory as well as
Visuoperceptual and Visuospatial Abilities than patients
with tAD. However, tAD patients showed greater impair-
ment in Delayed Auditory/Verbal Memory than patients
with PCA. PCA is characterized by significant atrophy of
the occipital and parietal regions and severe impairments in
visuospatial functioning.
Keywords Alzheimer’s disease (AD) . Posterior cortical
atrophy . Magnetic resonance imaging (MRI) . Voxel-based
morphometry (VBM) .Meta-analysis . Effect Size Signed
Differential Mapping (ES-SDM)
Introduction
The hallmark of typical Alzheimer’s disease (tAD) is the onset
of a specific pattern of episodic memory impairment (Clare et
al. 2003) that is associated with abnormalities in the entorhinal
cortex and hippocampus (Backman et al. 2004; Braak and
Braak 1991; Scahill et al. 2002; Yamasaki et al. 2012).
However, several studies have documented impairments
in other cognitive domains early in the progression of
Alzheimer’s disease, including executive function, con-
trolled inhibitory processes, verbal abilities, visuospatial
skills, attention and perceptual speed (Amieva et al. 2004;
Backman et al. 2004; Yamasaki et al. 2012).
Though the early stages of Alzheimer’s dementia are
traditionally characterized in terms of memory deficits,
nonamnestic presentations have also been considered in
diagnostic criteria such as those proposed by the National
Institute on Aging and the Alzheimer’s Association
(McKhann et al. 2011). Although brain pathology similar
to that in tAD is found in atypical, nonamnestic variants of
Alzheimer’s disease, unusual cognitive profiles have been
clinically observed. These variants have been consistently
described as affecting predominantly language or visuospa-
tial skills (Galton et al. 2000).
Electronic supplementary material The online version of this article
(doi:10.1007/s11682-013-9236-1) contains supplementary material,
which is available to authorized users.
J. Alves :A. Sampaio :Ó. F. Gonçalves
Neuropsychophysiology Lab, CIPsi, School of Psychology,
University of Minho, 4710-057 Braga, Portugal
J. M. Soares
Life and Health Sciences Research Institute (ICVS), School
of Health Sciences, University of Minho, Campus Gualtar,
4710-057 Braga, Portugal
J. M. Soares
ICVS/3B’s - PT Government Associate Laboratory,
Braga/Guimarães, Portugal
J. Alves (*)
Laboratório de Neuropsicofisiologia, Escola de Psicologia,
Universidade do Minho, Campus de Gualtar,
4710-057 Braga, Portugal
e-mail: jorge.alves@psi.uminho.pt
Brain Imaging and Behavior
DOI 10.1007/s11682-013-9236-1
One of the most frequently referred Alzheimer’s disease
variants is posterior cortical atrophy (PCA) (Benson et al.
1988). Neuroimaging in patients with PCA commonly
shows hypoperfusion, hypometabolism and/or atrophy of
occipital and parietal regions (Nestor et al. 2003). These
presentations may result in visuospatial symptoms, such as
apraxia, alexia and spatial neglect (see Kas et al. 2011, for
PCA diagnostic criteria based on McMonagle et al. 2006).
PCA is somewhat rare, as epidemiological estimates show
that PCA accounts for approximately 4 % of all new de-
mentia cases observed in a memory clinic (Croisile 2004).
Pathology studies report that most cases of PCA, upon
autopsy, show Alzheimer’s disease neuropathology
(Victoroff et al. 1994) with similar amyloid-b burden (de
Souza et al. 2011). As noted by Croisile (2004), Alzheimer’s
disease is characterized by underlying neuritic plaques and
neurofibrillary tangles, which can be present anywhere in
the brain and result in a diverse array of symptoms. Using
this rationale, PCA may be considered a visual variant of
Alzheimer’s disease. Similarly, differences in the distribu-
tion of amyloid deposits, neurofibrillary tangles and neuro-
nal loss may be responsible for the various clinical
presentations observed in Alzheimer’s disease.
Recent advances in neuroimaging methods and neuro-
psychological assessment techniques have led to improved
clinical descriptions of Alzheimer’s disease and increased
knowledge of its various presentations. For example, studies
of cortical density and thickness that directly compare PCA
and tAD have reported significantly more atrophy of the
visual association areas (e.g., the right parietal, bilateral
posterior parietal regions and the occipital lobe) in PCA.
Additionally, tAD patients were found to have greater vol-
ume decreases in the hippocampi and the left medial tem-
poral lobe (Feldmann et al. 2008; Lehmann et al. 2011;
Whitwell et al. 2007). Consistent with these findings, sev-
eral functional imaging studies provide evidence for de-
creased activation in visual attention areas and the
occipital lobes, as well as increased hypometabolism in the
inferior occipitotemporal cortex in PCA (Feldmann et al.
2008; Kas et al. 2011). Similarly, when compared to tAD
patients in structural imaging studies, PCA patients were
found to have a greater global amyloid load in occipital and
parietal regions as well as reduced white matter (WM)
integrity in posterior regions and severe WM occipital atro-
phy (Crutch et al. 2012; Formaglio et al. 2011; Migliaccio et
al. 2012a, b).
While these findings are intriguing, the results of
individual studies are inherently limited and may lack
sufficient statistical power due to small sample sizes,
the inclusion of heterogeneous subjects, or the use of
different clinical methods to make diagnostic classifica-
tions of the participants, which leads to discrepancies in
describing the etiology of the disorder. To address these
issues, tAD and PCA must be compared by a systematic
review and meta-analysis of the neuropsychological def-
icits and brain morphometry findings reported in the
literature.
Because previous studies report that patterns of brain
atrophy (e.g., medial temporal lobe, as shown by
Westman et al. 2011) are highly sensitive and specific
in diagnosing Alzheimer’s disease, we focused our study
in comparing brain morphometry patterns in tAD and PCA, as
well as the neuropsychological profiles associated with these
conditions.
Voxel-based morphometry (VBM) is an automated
whole-brain processing method, which allows the com-
position of brain tissue to be compared among (be-
tween and/or within) groups (Ashburner and Friston
2000). It has been used successfully in studies that
examine changes in white and gray matter (GM) that
occur in aging and several neuropsychiatric disorders.
Effect Size Signed Differential Mapping [ES-SDM]
(Radua et al. 2012) is a coordinate based meta-
analytic technique that may be applied in VBM meta-
analyses. ES-SDM accounts for within- and between-
study variance by combining peak coordinates and
statistical parametric maps. As Radua and Mataix-Cols
(2012) note, when comparing with regions of interest
methods, voxel-based methods although comparatively
less optimal in statistical terms, present the relevant
advantage of a more exhaustive and unbiased inclusion
of studies and brain regions.
The present meta-analysis aims to identify changes
in cerebral morphometry and cognitive abilities in
Alzheimer’s disease by using the ES-SDM (Radua et
al. 2012) and Open Meta-Analyst software (Wallace et
al. 2009) packages. The identification of these changes
will hopefully provide a detailed description of the
PCA variant, further differentiating it from tAD.
Methods
Data sources
A comprehensive literature search was independently
performed using PubMed, ScienceDirect and Web of
Knowledge (see Online Table 1 for detailed search terms).
No language or time restrictions were used in the search.
Additionally, the bibliographies of relevant reviews and
original articles were searched.
Studies selection
To be included in the meta-analysis, studies were re-
quired to have one PCA and one tAD group, which
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ranged from early to late-onset, though, the presence of
an HC group was not mandatory. Diagnoses of PCA
and tAD had to be specifically mentioned in the study
and performed according to established criteria (e.g. for
PCA: Kas et al. 2011; McMonagle et al. 2006; for AD:
McKhann et al. 1984; McKhann et al. 2011) (see
Table 1 for a summary of diagnostic criteria). Studies
reporting duplicate datasets were excluded. The present
study follows the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (Moher et al. 2009).
Abstracts and full articles were independently reviewed
for inclusion criteria by two of the authors (JA and JMS)
with discrepancies being solved through discussion.
Cognitive profiles
Neuropsychological studies were included if they
reported differential assessment of at least 1 PCA and
1 tAD (early or late-onset) group. Studies must also
have provided the means and standard deviations of
detailed neuropsychological assessments in at least 1
domain other than brief mental status tests or deteriora-
tion scales to be included. Studies returned by the
neuroimaging literature search were also inspected for
neuropsychological data. Full text articles or supplemen-
tary data were requested from authors when necessary.
Studies that did not provide sufficient data for analysis
were excluded.
Seven studies, which included a total of 104 PCA pa-
tients, 94 tAD patients and 76 HC, were included in the
present meta-analysis.
Neuroimaging
Inclusion criteria for neuroimaging studies were: 1) the
existence of group comparisons using whole-brain VBM
techniques, and 2) the presence of whole-brain group
comparisons of gray and/or white matter volume or
density via stereotactic coordinates corrected for multi-
ple comparisons (p<0.05). Four VBM studies, which
reported whole-brain comparisons of gray matter for a
total of 101 patients with PCA, 90 patients with tAD
and 173 HC were included in the final meta-analysis.
Table 1 Diagnostic criteria for typical AD and PCA—Summary of cardinal/defining features included in diagnostic criteria
AD (based on
McKhann et al. 1984)
AD—Amnestic presentation
(based on McKhann et al. 2011)
AD—Visuospatial presentation
(Nonamnestic) (based on
McKhann et al. 2011)
PCA (based on Kas et al. 2011;
and McMonagle et al. 2006)
Course and
presentation
Progressive dementing
disorder manifesting
in middle or late life.
Criteria for dementia should be
met with additional
characteristics of insidious
onset with clear-cut history of
worsening of cognition.
Criteria for dementia should be
met with additional
characteristics of insidious onset
with clear-cut history of
worsening of cognition.
Insidious onset and progressive
course of cognitive decline.
Typically an insidious
onset of dementia
with progressive
memory and other
cognitive deficits.
The initial and most prominent
cognitive deficits are in memory
(most common presentation of
AD). At least one other
cognitive domain is impaired.
The initial and most prominent
cognitive deficits are in the
visuospatial domain (e.g. spatial
cognition, object agnosia,
impaired face recognition,
simultanagnosia, alexia). Other
cognitive domains should be
impaired.
Marked visuospatial
dysfunction without
ophthalmologic impairment;
presence of Balint’s and/or
Gerstmann’s syndromes
symptoms. Proportionately
less memory loss or reduced
verbal fluency.
Considerations Other psychiatric,
neurological or
medical disorders
should not account
for the observed
deficits.
Diagnosis of probable AD dementia should not be applied when there
is evidence of substantial concomitant cerebrovascular disease, core
features of other type of dementia, or if a medication or medical
condition influencing cognition are present.
Focal neuroimaging lesions
(e.g. tumor, haematoma or
stroke) should be absent.
The clinical criteria
include Possible,
Probable, and
Definite Alzheimer’s
disease
Terminology includes: Probable AD; Possible AD dementia, and
Probable or possible AD dementia with evidence of the AD
pathophysiological process from (CSF or imaging) biomarkers.
Atypical course, and etiologically mixed presentations are also
considered.
The 2011 AD criteria revision includes non-amnestic presentations and
evidence of the AD pathophysiological process from (CSF or
imaging) biomarkers.
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Data extraction and data analysis
Neuropsychological data
OpenMeta-Analyst (Wallace et al. 2009) software was used
to calculate effect sizes and conduct tests of heterogeneity
for the included studies. Effect sizes were calculated using
standardized between-group mean differences in cognitive
performance and were measured using numerous neuropsy-
chological instruments (PCA vs. tAD, PCA vs. HC, tAD vs.
HC). Effect sizes were interpreted using Cohen’s d values
(0.2 = small; 0.5 = medium; 0.8 = large).
For each study included in our analysis, the number of
participants per group, as well as the mean scores and
standard deviations for each measure of cognitive ability
were recorded. This was performed for all comparisons of
neuropsychological test performance between patients with
PCA and tAD, PCA patients and HC, and tAD patients and
HC, when available.
We required that a minimum of two studies assess a
particular cognitive domain to consider that domain in our
analysis (see Online Table 2 for the tests used in each study
included by cognitive domain).
A detailed inspection of each study’s findings was
performed to integrate the neuropsychological data. The data
were grouped into the following cognitive domains: Global
Cognitive Functioning, Immediate Auditory/Verbal Memory,
Delayed Auditory/Verbal Memory, Immediate Visuospatial
Memory, Working Memory, Semantic Fluency, Phonemic
Fluency, Language–Naming, Language–Comprehension,
Visuoperceptive and Visuospatial Abilities, Ideomotor Praxis.
For each cognitive domain, pooled effect sizes were calcu-
lated using fixed-effects modeling or, in the case of substantial
heterogeneity (I2>50 %), random-effects (DerSimonian, and
Laird 1986) modeling. Because fewer than ten studies were
included for each meta-analysis, subgroup analysis, meta-
regression and analyses of publication bias, which use the
Funnel Plot and Eggers’ test, were not performed.
Neuroimaging data
The ES-SDM method (Radua et al. 2012) was used for the
voxel-based meta-analysis. This method generates a coordi-
nate map of GM differences, which are statistically signifi-
cant at the whole-brain level and corrected for multiple
comparisons, for each study. This map includes difference
values that are both positive and negative; this prevents a
single voxel to be significant in opposite directions. The
mean of each study map, weighted by the square root of
each study’s respective sample size, was computed. This
ensures that each study contributes proportionally to the
resulting meta-analytic maps. In the preprocessing step,
and in order to control for false-positives, a relatively wide
full-width at half-maximum (FWHM, 20 mm) was used and
the statistical threshold was set to p<0.005 (Radua et al.
2012). To test the replicability of the results, a systematic
whole-brain voxel-based jackknife sensitivity analysis was
performed.
Results
Included studies
Four neuroimaging (Feldmann et al. 2008; Lehmann et al.
2011; Migliaccio et al. 2009; Whitwell et al. 2007) and eight
neuropsychological (Aresi and Giovagnoli 2009; Caprile et
al. 2009; Charles and Hillis 2005; Croisile et al. 2010; Kas
et al. 2011; McMonagle et al. 2006; Migliaccio et al. 2009;
Nestor et al. 2003;) studies met inclusion criteria (See
Online Fig. 1 for the detailed flow diagram).
Five studies reported neuropsychological data for PCA,
tAD and HC groups (see Online Table 2 for further details).
All four neuroimaging studies reported data for these three
groups as well. However, only two of the neuroimaging
studies provided comparisons between PCA and tAD direct-
ly. The Croisile et al. (2010) study was not included in the
Table 2 Statistically significant effects results of PCA vs AD meta-analysis of cognitive domains
Cognitive domain Studies
(k)
Participants
(n)
Statistical method Estimated effect
(95 % CI)
Heterogeneity
Index (I2)
Delayed auditory/verbal
memory
4 102 Standardized Mean Difference (Fixed
Effects, 95 % CI)
0.716 (0.313, 1.119) 0 %
p<0.001
Immediate visuospatial memory 2 42 Standardized Mean Difference (Fixed
Effects, 95 % CI)
−0.772 (−1.399,
−0.145)
0 %
p=0.016
Visuoperceptive and
visuospatial abilities
5 88 Standardized Mean Difference (Random
Effects, 95 % CI)
−2.124 (−3.546,
−0.702)
83 %
p=0.003
Negative effect sizes are interpreted as PCA group showing more impairment (higher test scores meaning best outcome)
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neuropsychological meta-analysis due to a large disparity in
sample sizes for the mild-to-moderate Alzheimer’s disease
and PCA groups (n=402, n=84 vs. PCA=16), resulting in
seven neuropsychological studies (of eight meeting inclu-
sion criteria) being included for the meta-analysis.
The studies included for analysis reported a mean Mini-
Mental State Exam (MMSE) score greater than 14. The
demographic and brief mental status data of the participants
from all studies included in the analysis are presented in
Online Table 3. The estimated mean difference of the MMSE
yielded no significant differences in the amount of cognitive
deterioration (MD=−0.820, p=0.226) between the PCA and
tAD groups. However, the VBM studies reported greater
cognitive deterioration (MD=1.838, p=0.011) in the tAD
group. One study (Whitwell et al. 2007) could not be included
in this estimate because it did not provide mean values.
A total of 205 PCA patients, 184 tAD patients, and 249
HC participants were included in this study.
For each dataset, HC patients for comparison with PCA
and tAD groups were the same for both groups, which
would yield comparable global findings.
Neuropsychological profile
In most of the assessed domains, profiles of global cognitive
impairments were observed in the PCA and tAD patient
groups (see Online Tables 4 and 5 and 6 for detailed results).
Compared to tAD patients, PCA patients exhibited signifi-
cantly greater impairment in Immediate Visuospatial
Memory (Standardized mean difference[SMD]=−0.772,
p=0.016, I2=0 %), as well as Visuoperceptive and
Visuospatial Abilities (SMD=−2.124, p=0.003, I2=83 %).
However, tAD patients showed significantly greater im-
pairment in Delayed Auditory/Verbal Memory than patients
with PCA (SMD=0.716, p<0.001, I2=0 %; see Table 2 for
statistically significant results; see Online Table 6 for de-
tailed results).
Brain morphometry (Gray matter VBM meta-analysis:
whole-brain gray matter differences between tAD, PCA
and HC)
Only studies with VBM volumetric assessment were found
in the literature (i.e. no studies using other segmentation
methods—e.g., FreeSurfer, FSL—were found).
Studies included in the meta-analysis indicated reduc-
tions of gray matter volume in the middle and superior
temporal gyri, the fusiform gyrus extending to the left
caudate tail and in the left parahippocampal gyrus extending
to the globus pallidus and putamen, which was significantly
greater for tAD patients than for HC participants. Compared
to HC, PCA patients exhibited significantly greater gray
matter reductions in the inferior and medial left temporal
gyri extending to the occipital gyrus. Gray matter volume
reductions were also observed in PCA patients in the left
fusiform and parahippocampal gyri as well as the right
parietal lobule, including the inferior middle and superior
parietal and angular gyri. However, when compared to tAD
Sagital section Coronal section Axial section
Fig. 1 Comparison of GM
atrophy between PCA and AD
groups. Blue: Greater atrophy
in PCA vs AD; Red: Greater
atrophy in AD compared
to PCA. Neurologic view
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patients, PCA patients showed significant decreases in gray
matter volume in the middle and inferior right occipital gyri,
extending to the posterior lobule. PCA patients also
exhibited greater volume sparing in the left parahippocampal
gyrus and the left hippocampus (Fig. 1 illustrates the re-
sults from the comparison between the PCA and tAD
groups; for a comparison between PCA, tAD and HC
groups, see Online Fig. 2).
The replicability of these results was assessed using a
systematic whole-brain voxel-based jackknife sensitivity
analysis, which was based on the exclusion of one study
per iteration. As presented in Table 3, this analysis showed
that the main results of this study were replicable.
Discussion
To the best of our knowledge this is the first meta-
analysis providing a characterization of both neuropsy-
chological and brain morphometric features of PCA
when compared with typical tAD and HC.
Compared to HC, PCA patients showed atrophy of brain
areas similar to tAD patients. In particular, volume loss was
observed in the left fusiform, left parahippocampal gyrus and
left middle temporal gyrus, which represents a shared pattern
of wide temporal atrophy. PCA patients exhibited significant-
ly more atrophy in the right occipital gyrus and right posterior
lobe than tAD patients, whereas atrophy in the left
parahippocampal gyrus and hippocampus was greater in the
tAD group. Moreover, these neuroimaging data were consis-
tent with findings from the neurocognitive literature; individ-
uals with PCA showed higher levels of impairment in
Visuoperceptive and Visuospatial Abilities and Immediate
Visuospatial Memory. In addition, tAD patients presented
with greater impairments in Delayed Auditory/Verbal
Memory. These findings support an association between neu-
ral atrophy and the cognitive deficits observed in PCA and
tAD.
PCA and tAD probably result from the same neuro-
degenerative process. While PCA and tAD share some
regions of brain atrophy, the patterns of atrophy and
neuropsychological characteristics of these conditions
Table 3 Gray matter differences between PCA, AD and HC
Comparison Region Maximum Cluster Jackknife
sensitivity analysis
Talairach
coordinates x y z
SDM
value
P value Number of
voxels
Breakdown (number of voxels)
AD vs
Controls
Left temporal gyrus −34 −26 −6 −2.762 0.00002 358 Left caudate, caudate tail (12) 3 out of 4
Left sub-gyral hippocampus (34) 3 out of 4
Left middle temporal gyrus (63) 3 out of 4
Left superior temporal gyrus (76) 3 out of 4
Left fusiform gyrus (52) 3 out of 4
Left
parahippocampal
gyrus
−16 −6 −16 −1.679 0.001 292 Left parahippocampal gyrus (86) 4 out of 4
Left lentiform nucleus, medial
globus pallidus (51)
2 out of 4
Left lentiform nucleus, putamen
(15)
3 out of 4
PCA vs
Controls
Left inferior
temporal gyrus
−46 −68 0 −2.199 0.0001 80 Left inferior temporal gyrus (22) 3 out of 4
Left middle temporal gyrus (29) 3 out of 4
Left middle occipital gyrus (19) 3 out of 4
Left fusiform gyrus −28 −48 −10 −2.186 0.0001 204 Left fusiform gyrus (39) 3 out of 4
Left parahippocampal gyrus (45) 3 out of 4
Right inferior
parietal lobule
42 −46 38 −1.870 0.0007 457 Right inferior parietal lobule (168) 2 out of 4
Right middle temporal gyrus (111) 2 out of 4
Right superior temporal gyrus (57) 2 out of 4
Right angular gyrus (66) 2 out of 4
PCA vs AD Right middle
occipital gyrus
48 −78 −6 −1.007 0.0003 173 Right middle occipital gyrus (16)
Right inferior occipital gyrus (91)
Right posterior lobe (57)
Left
parahippocampal
gyrusa
−34 −18 −12 1.007 0.0004 318 Left parahippocampal gyrus, hippocampus (24)
Left parahippocampal gyrus (121)
a Increased gray matter
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may differ. Both of these variants can be distinguished
by structural neuroimaging and neuropsychological
assessment.
The findings of this study support previous neuropsycho-
logical studies (Galton et al. 2000) and reviews (Crutch et al.
2012), which show that compared to tAD, the mild-to-
moderate stages of PCA are characterized by severe deficits
in visuospatial abilities, which distinguish it from typical
tAD (where there is comparably more impairment in
Delayed Auditory/Verbal Memory). These data corroborate
findings from neuroimaging studies, which localize brain
atrophy to predominantly posterior areas (Crutch et al.
2012). Specifically, atrophy of occipital and parietal regions
may result in the visuospatial deficits that have been previ-
ously described in PCA (Crutch et al. 2012). In addition,
functional neuroimaging studies have shown a pattern of
hypometabolism and functional underactivation (Crutch et
al. 2012; Feldmann et al. 2008) in posterior areas (the
parietal and/or occipital lobes). This could potentially be
related to the increased deposition of senile plaques in these
areas observed in PCA (Crutch et al. 2012).
In the present study, PCA patients exhibited more marked
volume reduction than that for tAD patients in the right
occipital gyrus (middle, inferior and posterior occipital
lobe). The mechanisms underlying this pattern of atrophy
remain unclear.
In tAD patients, extensive atrophy was observed in the
medial temporal lobe, in particular, the left hippocampal
region, which has previously been associated with impair-
ments in encoding and retrieval of episodic memory
(Yamasaki et al. 2012). Although brain atrophy was limited
to the temporal, parietal and occipital lobes of PCA patients,
we observed a global pattern of cognitive impairment when
compared to HC (e.g., impairment in Semantic and
Phonemic Fluency). Besides indicating memory impair-
ments, these fluency deficits are also indicative of executive
impairments. While no atrophy was found in the frontal
lobes of PCA patients, it is possible that functional
underactivation of this area may underlie these deficits and
precede structural abnormalities. Functional impairments,
such as hypometabolism, may be present during earlier
stages of the disease (Nestor et al. 2003). They may even-
tually progress to frank structural damage, possibly begin-
ning in the milder stages of the disease or later.
Another intriguing cognitive aspect is the relationship
between visual memory and visuoperceptive and visuospa-
tial abilities. While the possibility of visuoperceptive defi-
cits originating the marked pattern of visual memory
dysfunction in PCA patients seems viable, this remains a
plausible hypothesis to be tested. In the present study, PCA
patients showed more marked deficits in immediate visuo-
spatial memory, visuoperceptive and visuospatial abilities
than tAD; while AD patients showed marked deficits in
Immediate Auditory/Verbal Memory, when compared with
PCA. Unfortunately, it was not possible to perform an
analysis regarding the delayed visuospatial memory domain
in PCA patients due to the lack of a minimum of 2 studies
with compatible cognitive tests for this domain. Future
research, extensively characterizing the natural course of
visual memory deficits and each cognitive function might
clarify this issue.
Additionally, and consistent with previous studies, we
found atrophy in the globus pallidus and putamen. For
example, Josephs et al. (2006) reported evidence of atrophy
in globus pallidus that may be associated with visual hallu-
cinations. Whitwell et al. (2007) found also evidence for
extended atrophy in regions spreading from the parietal
lobes to primary sensory and motor cortex. However, the
full clinical meaning of atrophy in these regions remains to
be clarified.
GM atrophy may progress from a focal to a global
presentation, which is not confined to areas associated with
the initial symptomatology (Lehmann et al. 2012) of PCA
and tAD. This may be congruent with the spread of pathol-
ogy observed over time in these conditions as well.
Morphometric changes can also occur in the WM. For
example, PCA reduces the integrity of WM tracts in poste-
rior brain regions. This may result in network-level dysfunc-
tions affecting the major visual pathways predominantly in
the right hemisphere (Crutch et al. 2012; Migliaccio et al.
2012a, b).
Some limitations of the present study should be acknowl-
edged. First, patients sampled in the studies used for this
analysis differed in the stage and/or severity of the disease,
as evidenced by different MMSE scores. In addition, only a
limited number of studies were appropriate for analysis,
which is especially true for the neuroimaging literature,
which discourages performing sub-group analysis or meta-
regression. Therefore, it was not possible to perform a
thorough assessment of the impact of variables such as
age, gender, education and MMSE in the observed results.
Similarly, the relation between specific domains (e.g. imme-
diate visual memory and visuoperceptive and visuospatial
abilities) and the characterization of some specific cognitive
functions (e.g. delayed visuospatial memory) could not be
currently established. Because the frequency of PCA pre-
sentation is relatively low, PCA is likely to be under recog-
nized and understudied. Moreover, the PCA entity has some
circularity since the diagnostic criteria used for PCA de-
mands visuospatial dysfunction in excess of episodic mem-
ory dysfunction, with the name of the diagnostic entity
predicting the regionally specific atrophy pattern. We hope
that our analysis of the neuropsychological and imaging
data will improve the diagnostic and clinical understandings
of PCA and contribute to the nosological and etiological
characterization of each type of dementia presentation
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through the inclusion of detailed quantitative neuroimaging
and neuropsychological PCA profiles in diagnostic criteria.
In this regard, we believe that the standardization of cogni-
tive and neuroimaging parameters (e.g. obtaining group
mean values for each cognitive domain and neuroimaging
parameter—e.g. volumetry—throughout the course of the
disease) for each AD variant and other dementias might be
an important aspect allowing to empirically define the PCA
profile and other variants of AD. This way it would be
possible to quantify how much a set of cognitive
functions/domains and structural and functional neuroimag-
ing parameters (e.g. hippocampal, parietal, occipital vol-
ume, etc.) deviate from a set of normative values. These
comparisons could be performed either at the inter-dementia
class or within each dementia (e.g. between AD variants).
For example, a clinician might be able to generate memory
and hippocampal volume z-scores for the patient with
suspected PCA and compare it with a set of standardized
values of healthy subjects, AD and other dementia patients.
Similarly, the same comparison would be generated for
other cognitive domains and structures allowing to choose
the more probable diagnosis based on intra and inter-
dementia comparisons.
Further longitudinal follow-up studies are necessary
to understand the natural progression of PCA, as well as
its different neural (atrophy, abnormal fMRI/PET brain
activation patterns) and cognitive markers that charac-
terize the stages of PCA. Once the imaging correlations
and changes in cognitive profiles in PCA are more fully
described, diagnostic accuracy and clinical care of the
disorder may be improved.
Reliable markers to diagnose PCA are presented in our
analysis. Because cognitive testing and structural MRI may
be more readily available and less expensive than other
imaging techniques (e.g. PET imaging), we believe that
using these markers may be potentially efficacious in the
diagnosis of PCA. Moreover structural changes such as
synaptic/neuronal loss correlate better than plaques or tan-
gles with cognitive deficits (Shankar and Walsh 2009; Terry
et al. 1991). Structural pathology databases may one day be
worldwide available in clinical settings to make automatic
comparisons of brain volume loss, which could assist in the
identification of PCA.
In summary, PCA is characterized by a global profile of
cognitive impairment, marked by visuospatial deficits. In
particular, PCA can be distinguished from tAD by GM
changes and marked deficits in Visuoperceptive and
Visuospatial Abilities and Immediate Visuospatial Memory.
Additionally, tAD is characterized by impairments in Delayed
Auditory/Verbal Memory, as well as temporal lobe atrophy.
As Crutch et al. (2012) noted, PCA is a focal degenerative
syndrome, which lacks consistent and standardized diagnostic
criteria. In this study we provided a systematic review of the
neural and cognitive correlates of PCA.We also demonstrated
that global cognitive impairments are observed in this condi-
tion, the most severe of which is visuospatial dysfunction.
The findings of this study could help to elucidate the
current debate surrounding the classification of PCA as
Alzheimer’s disease visual variant and allow for a better
understanding and awareness of PCA and a more standard-
ized diagnosis. We hope this work may provide working
hypotheses and promote new research in this field, since the
current limited amount of data precludes the establishment
of well-founded conclusions, which would advance diag-
nostic and treatment guidelines.
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